Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
13 March 2012Website:
http://orgenesis.comNext earnings report:
21 May 2025Last dividends:
N/ANext dividends:
N/APrice
regular market | Tue, 19 Nov 2024 20:26:59 GMTDividend
Analysts recommendations
Institutional Ownership
ORGS Latest News
Orgenesis' CD19 CAR-T therapy, ORG-101, had a complete response (CR) of 82% in adults and 93% in pediatric patients with the incidence of severe Cytokine Release Syndrome (CRS) of 2% in adult patients and 6% in pediatric patients in a real-world study
The strategic alliance aims to drive new-age innovation in wellness & longevity, backed by an investment commitment of up to $10 million over 3 years into both Orgenesis and the newly formed joint venture The strategic alliance aims to drive new-age innovation in wellness & longevity, backed by an investment commitment of up to $10 million over 3 years into both Orgenesis and the newly formed joint venture
What type of business is Orgenesis?
Orgenesis Inc., a biotech company, focuses on cell and gene therapies worldwide. It operates through two segments, Octomera and Therapies. The company develops a Point of Care (POCare) platform that includes a pipeline of licensed cell based POCare therapies that are processed and produced under closed and automated POCare technology systems across a collaborative POCare network consisting of research institutes and hospitals. Its therapies include autologous; cell-based immunotherapies; and therapeutics for metabolic diseases, anti-viral diseases, and tissue regeneration. The company also provides development services, including regulatory services, pre-clinical studies, intellectual property services, and GMP process translation, as well as support services; hospital services; cell process development services; and distributed cell processing services. The company was formerly known as Business Outsourcing Service, Inc. and changed its name to Orgenesis Inc. in August 2011. Orgenesis Inc. was incorporated in 2008 and is headquartered in Germantown, Maryland.
What sector is Orgenesis in?
Orgenesis is in the Healthcare sector
What industry is Orgenesis in?
Orgenesis is in the Biotechnology industry
What country is Orgenesis from?
Orgenesis is headquartered in United States
When did Orgenesis go public?
Orgenesis initial public offering (IPO) was on 13 March 2012
What is Orgenesis website?
https://orgenesis.com
Is Orgenesis in the S&P 500?
No, Orgenesis is not included in the S&P 500 index
Is Orgenesis in the NASDAQ 100?
No, Orgenesis is not included in the NASDAQ 100 index
Is Orgenesis in the Dow Jones?
No, Orgenesis is not included in the Dow Jones index
When was Orgenesis the previous earnings report?
No data
When does Orgenesis earnings report?
The next expected earnings date for Orgenesis is 21 May 2025